- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: BMS-901608, PDL063, HuLuc63
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 0 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
|
References |
|---|
| CAS No. | 915296-00-3 |
|---|---|
| Molecular Weight | 145 kD |
| Isotype | Human IgG1, κ |
| Source | CHO cells |
| Sterility | 0.2 μM filtered |
| Formulation | PBS Buffer, PH 7.4 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.